This is a demo store. No orders will be fulfilled.
USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Life Sciences
Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas
The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.
Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.
The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.
We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.
We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.
-
The market for regenerative medicine, one of the fastest growing segments in the biotechnology industry, is estimated to reach $67.5 billion by 2020 recording a compound annual growth rate (CAGR) of 22%. Current industry trends signal the expanding horizons of regenerative medicine, with its application being explored in new therapeutic segments su...
$1,500.00 -
Immunoglobulin (Ig) therapies are among the oldest therapeutic moieties employed in a broad range of pathological conditions. Immunoglobulin G (IgG) holds the highest share (44%) in the global blood plasma market, with a revenue of $9.24 billion. Currently, the global Ig market is dominated by three major companies, holding about 85% of the total m...
$1,500.00 -
30 Jun 2016 | Global | Market Research
Vital Signs The Analyst's Perspective - May 2016 Issue
This Vital Signs issue discusses Sinocare's acquisition of PTS Diagnostics, biosimilar drug pricing, Americans' usage of prescription pain killers, and Takara Bio's acquistion of Wafergen Bio-systems.
$450.00 -
27 Jun 2016 | Global | Market Research
Market Assessment of MRI Equipment and its Emerging Clinical Applications
The global MRI market is currently experiencing steady growth (mid-single digit growth rate). Although economic uncertainty and budgetary constraints have slowed down the market in certain countries, technological innovation and extended/new clinical applications of MRI due to their high importance in the imaging space have enabled it to overcome t...
$4,950.00 -
05 May 2016 | Global | Market Research
Future of Global Retail Healthcare Delivery Markets, Forecast to 2022
Escalating Demand for Low-cost Alternatives to Create Market Size of Nearly $4 Billion
Retail healthcare entails primary care services for minor illnesses provided through clinics located in retail environments, such as a pharmacies, grocery chains, supermarkets, or departmental stores. These retail care clinics, also called convenient care clinics, walk-in clinics, or in-store clinics, are often open beyond regular operating hours o...
$3,000.00 -
04 Apr 2016 | Global | Market Research
Vital Signs - Emerging Trends and Opportunities in Life Sciences, February 2016
Exciting Developments in Generic Drug Pricing, CRISPR Technology, GenomeAsia 100K and Large-scale Next-generation Sequencing Projects, and Medicare Outcomes
This Vital Signs issues discusses generic drug pricing, CRISPR technology, GenomeAsia 100K and large-scale next-generation sequencing projects, and Medicare outcomes target.
$450.00 -
29 Mar 2016 | Global | Market Research
Top 50 Emerging Technologies: Growth Opportunities of Strategic Imperative
Multi-billion dollar technologies ready to propel industries and transform our world
Research Overview The Top 50 Emerging Technologies research is a comprehensive analysis of the most promising and disruptive technologies poised to impact our world in the next few years. It highlights and offers strategic guidance and actionable ideas on the hottest 50 technologies that pack maximum potential to fuel global innovation; spawn in...
$7,500.00 -
05 Jan 2016 | Global | Market Research
Vital Signs - Advances in Cancer Treatment, Clampdown on Specialty Pharmacies and Strategy Revamp for Sequencing Provider, An Analysis
Liquid Biopsy Test for Prostate Cancer and Non-small Cell Lung Cancer Treatment Show Promise
This issue of Vital Signs discusses MDxHealth's launch of the SelectMDx Liquid Biopsy Test in Europe, the FDA's approval of a new treatment for non-small cell lung cancer with EGFR mutations, the clamp down on specialty pharmacies by US drug benefit managers, and BGI's strategy redirection for Complete Genomics.
$450.00
